Literature DB >> 25772830

The differences between two selected intensive care units located in central and northern Europe - preliminary observation.

Jan Adamski, Radosław Goraj, Dariusz Onichimowski, Ewa Gawlikowska, Wojciech Weigl1.   

Abstract

BACKGROUND: The aim of this study was to evaluate possible differences in the functioning of two selected intensive care units in Poland and Finland. The activity of the units was analysed over a period of one year.
METHODS: The following parameters were compared: demography of treated populations, site of admission, category of illness, severity of illness (APACHE-II scale), mean length of stay, demanded workload (TISS-28 scale), mortality (both ICU and hospital) and standardized mortality ratio (SMR).
RESULTS: The results of this study indicated that most of the patients in the Polish ICU, regardless of age, diagnosis and APACHE II score, presented significantly longer lengths of stay (14.65 ± 13.6 vs 4.1 ± 4.7 days, P = 0.0001), higher mean TISS-28 score (38.9 ± 9.1 vs 31.2 ± 6.1, P = 0.0001) and higher ICU and hospital mortality (41.5% vs 10.2% and 44.7% vs 21.8%, respectively, P = 0.0001). The values of SMR were 0.9 and 0.85 for the Finnish and Polish ICUs, respectively.
CONCLUSION: The collected data indicate huge differences in the utilisation of critical care resources. Treatment in Polish ICU is concentrated on much more severely ill patients which might be sometimes accompanied by futility of care. In order to verify and correctly interpret the presented phenomena, further studies are needed.

Entities:  

Mesh:

Year:  2015        PMID: 25772830     DOI: 10.5603/AIT.a2015.0010

Source DB:  PubMed          Journal:  Anaesthesiol Intensive Ther        ISSN: 1642-5758


  8 in total

Review 1.  [Quality assurance concepts in intensive care medicine].

Authors:  A Brinkmann; J P Braun; R Riessen; R Dubb; A Kaltwasser; T M Bingold
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-10-26       Impact factor: 0.840

Review 2.  Mortality rate is higher in Polish intensive care units than in other European countries.

Authors:  Wojciech Weigl; Jan Adamski; Paweł Goryński; Andrzej Kański; Michael Hultström
Journal:  Intensive Care Med       Date:  2017-05-08       Impact factor: 17.440

3.  Mortality rate in Polish intensive care units is lower than predicted according to the APACHE II scoring system.

Authors:  Piotr Knapik; Łukasz J Krzych; Wojciech Weigl; Jan Adamski; Michael Hultstöm
Journal:  Intensive Care Med       Date:  2017-07-21       Impact factor: 17.440

4.  Routine Treatment-Resistant Clostridium difficile Infection during Recovery from Myxedema.

Authors:  Jan K Adamski; Björn B Jäschke; Raija S Uusitalo-Seppälä; Kalle V J Moilanen; Antti V Pehkonen; Wojciech Weigl
Journal:  Case Rep Gastroenterol       Date:  2017-11-29

5.  Should we admit more patients not requiring invasive ventilation to reduce excess mortality in Polish intensive care units? Data from the Silesian ICU Registry.

Authors:  Piotr Knapik; Małgorzata Knapik; Ewa Trejnowska; Bogumiła Kłaczek; Konstanty Śmietanka; Daniel Cieśla; Łukasz J Krzych; Ewa M Kucewicz
Journal:  Arch Med Sci       Date:  2019-05-08       Impact factor: 3.318

6.  Readmissions to General ICUs in a Geographic Area of Poland Are Seemingly Associated with Better Outcomes.

Authors:  Marek Grochla; Wojciech Saucha; Daniel Ciesla; Piotr Knapik
Journal:  Int J Environ Res Public Health       Date:  2020-01-16       Impact factor: 3.390

7.  The Pros and Cons of the Prediction Game: The Never-ending Debate of Mortality in the Intensive Care Unit.

Authors:  Piotr A Fuchs; Iwona J Czech; Łukasz J Krzych
Journal:  Int J Environ Res Public Health       Date:  2019-09-13       Impact factor: 3.390

8.  Feasibility of Chest Wall and Diaphragm Proprioceptive Neuromuscular Facilitation (PNF) Techniques in Mechanically Ventilated Patients.

Authors:  Tomasz Zwoliński; Magdalena Wujtewicz; Jolanta Szamotulska; Tomasz Sinoracki; Piotr Wąż; Rita Hansdorfer-Korzon; Andrzej Basiński; Rik Gosselink
Journal:  Int J Environ Res Public Health       Date:  2022-01-15       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.